Marchés français ouverture 5 h 32 min

Sanofi (SNYNF)

Other OTC - Other OTC Prix différé. Devise en USD
Ajouter à la liste dynamique
103,00-5,84 (-5,37 %)
À la clôture : 10:21AM EDT

Sanofi

54, Rue La BoEtie
Paris 75008
France
33 1 53 77 40 00
https://www.sanofi.com

Secteur(s)Healthcare
Secteur d’activitéDrug Manufacturers—General
Employés à temps plein95 442

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. Paul HudsonCEO & Director5,88MS.O.1967
Mr. Jean-Baptiste Chasseloup de ChatillonExec. VP & CFOS.O.S.O.1965
Mr. Laurent GilhodesPrincipal Accounting Officer and VP of Corp. AccountingS.O.S.O.S.O.
Mr. Bruno MénardChief Information officerS.O.S.O.S.O.
Dr. Josephine FubaraChief Science Officer of Consumer Health CareS.O.S.O.S.O.
Eva Schaefer-JansenHead of Investor RelationsS.O.S.O.S.O.
Mr. Dante BeccariaGlobal Compliance Officer & VPS.O.S.O.S.O.
Mr. Roy PapatheodorouExec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. IntegrityS.O.S.O.1978
Mr. Josep CatllaHead of CommunicationsS.O.S.O.S.O.
Mr. Pierre ChancelSr. VP of Global Diabetes and Sr. VP of Global MarketingS.O.S.O.1957
Les montants ont été établis en date du 31 décembre 2021 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Sanofi en date du 1 juillet 2022 est 3. Les scores principaux sont Audit : 3; Société : 5; Droits des actionnaires : 5; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.